Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Sorrento Therpt (SRNE)

Sorrento Therpt (SRNE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 824,566
  • Shares Outstanding, K 388,946
  • Annual Sales, $ 52,900 K
  • Annual Income, $ -428,330 K
  • 60-Month Beta 2.22
  • Price/Sales 21.43
  • Price/Cash Flow N/A
  • Price/Book 7.22
Trade SRNE with:

Options Overview Details

View History
  • Implied Volatility 107.55% ( +8.08%)
  • Historical Volatility 96.03%
  • IV Percentile 54%
  • IV Rank 12.06%
  • IV High 400.53% on 05/24/22
  • IV Low 67.36% on 09/23/21
  • Put/Call Vol Ratio 0.22
  • Today's Volume 15,667
  • Volume Avg (30-Day) 6,159
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 242,359
  • Open Int (30-Day) 230,716

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.23
  • Number of Estimates 2
  • High Estimate -0.20
  • Low Estimate -0.25
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +30.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.06 +2.91%
on 08/17/22
3.09 -31.39%
on 07/20/22
-0.48 (-18.46%)
since 07/15/22
3-Month
1.35 +57.04%
on 06/14/22
3.09 -31.39%
on 07/20/22
+0.55 (+35.03%)
since 05/17/22
52-Week
1.15 +84.35%
on 05/12/22
9.63 -77.99%
on 08/25/21
-6.39 (-75.09%)
since 08/17/21

Most Recent Stories

More News
Aridis Pharmaceuticals (ARDS) Reports Q2 Loss, Misses Revenue Estimates

Aridis Pharmaceuticals (ARDS) delivered earnings and revenue surprises of -650% and 97.21%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ARDS : 1.8300 (-10.29%)
SRNE : 2.12 (-15.87%)
Albireo Pharma (ALBO) Reports Q2 Loss, Misses Revenue Estimates

Albireo Pharma (ALBO) delivered earnings and revenue surprises of -29.11% and 12.89%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

ALBO : 17.72 (-1.99%)
SRNE : 2.12 (-15.87%)
Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates

Urogen Pharma (URGN) delivered earnings and revenue surprises of 11.28% and 2.02%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

URGN : 8.30 (-1.43%)
SRNE : 2.12 (-15.87%)
Rani Therapeutics Holdings, Inc. (RANI) Reports Q2 Loss, Misses Revenue Estimates

Rani Therapeutics Holdings, Inc. (RANI) delivered earnings and revenue surprises of -10.71% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the...

RANI : 11.01 (-7.87%)
SRNE : 2.12 (-15.87%)
Sorrento Completes Successfully the SAD Study and Initiates the MAD Phase 1 Study with STI-1558, An Oral M(pro) Inhibitor as a Standalone Treatment and Prevention of COVID-19 without the Ritonavir as Booster

Single ascending dose (SAD) Phase 1 Study completed in Australia with a maximum dose of 2,000 mg.Pharmacokinetics (PK) were dose proportional and PK...

SRNE : 2.12 (-15.87%)
Sorrento (SRNE) Rises on FDA IND Clearance for COVID Drug

Sorento Therapeutics (SRNE) receives IND application clearance from the FDA for a phase I study evaluating STI-1558 for COVID-19.

ALKS : 25.61 (-3.18%)
SGEN : 170.79 (+0.16%)
SRNE : 2.12 (-15.87%)
BNTX : 152.04 (-5.19%)
Sorrento Therapeutics Announces the FDA IND Clearance of STI-1558, An Oral M(pro) and Cathepsin L Inhibitor to Treat COVID-19

STI-1558, an oral SARS-CoV-2 main protease inhibitor which can block viral replication, is specifically designed as a standalone treatment of...

SRNE : 2.12 (-15.87%)
Why Ocugen, Sorrento Therapeutics, and VBI Vaccines Are on the Move Today

Healthcare has become a bona fide stock picker's market this year.

JPM : 122.59 (-0.84%)
OCGN : 2.67 (-3.61%)
SRNE : 2.12 (-15.87%)
VBIV : 1.2300 (-5.38%)
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Amgen (AMGN) and Sorrento Therapeutics (SRNE)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amgen (AMGN – Research Report) and Sorrento Therapeutics (SRNE – Research Report). Amgen (AMGN) In a report released...

AMGN : 250.58 (-1.02%)
SRNE : 2.12 (-15.87%)
Scilex Holding Company, a Sorrento Company, Has Entered A Term Sheet to Acquire Ancora Medical Inc.

Ancora Medical Inc. (“Ancora”) is a privately held medical technology company with an FDA approved product in February 2020, the Nerve Block Catheter Set...

SRNE : 2.12 (-15.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Sorrento Therapeutics, Inc. is a biopharmaceutical company. It is focused primarily on the acquisition, discovery, development and commercialization of proprietary oncology therapeutics. The Company researches human therapeutic antibodies for the treatment of cancer, inflammation, metabolic disease and...

See More

Key Turning Points

3rd Resistance Point 2.85
2nd Resistance Point 2.68
1st Resistance Point 2.40
Last Price 2.12
1st Support Level 1.95
2nd Support Level 1.78
3rd Support Level 1.50

See More

52-Week High 9.63
Fibonacci 61.8% 6.39
Fibonacci 50% 5.39
Fibonacci 38.2% 4.39
Last Price 2.12
52-Week Low 1.15

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar